NAME- KUMAR SURAJ

ROLL NO - 22
SEC- A

Type Public (BSE: 500087)

Industry Pharmaceuticals

Founded 1935

Headquarters Mumbai, India

Key people Y. K. Hamied (CMD), Chairman

Products Pharmaceuticals and diagnostics

Revenue ▲   5,624.91 crore (US$1.27 billion)(2010)[1]

Net income ▲   1,082.59 crore (US$243.58 million)(2010)

Employees 8500

1
HISTORY
Khwaja Abdul Hamied, the founder of Cipla, was born on October 31, 1898.

In 1935, he set up The Chemical, Industrial & Pharmaceutical Laboratories, which came to be
popularly known as Cipla. He gave the company all his patent and proprietary formulas for
several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was
registered as a public limited company with an authorized capital of Rs 6 lakhs.

CEO
DR.Y.K.HAMIED

CFO
S.RADHAKRISHNAN

TURNOVER
Cipla to cross rs.6000cr. turnover.

AREAS
MEDICINES

GLOBAL PRESENCE
Exports for the financial year ended March 31, 2009 amounted to more than Rs. 27,500
million. Cipla exports raw materials, intermediates, prescription drugs, OTC products and
veterinary products. Cipla also offers technology for products and processes. Technical
know-how/fees received during the year 2008-09 amounted to about Rs. 2200 million 
Cipla's manufacturing facilities have been approved by the following regulatory
authorities.

2
Exports for the financial year ended March 31, 2009 amounted to more than Rs.
27,500 million. Cipla exports raw materials, intermediates, prescription drugs, OTC

products and veterinary products. Cipla also offers technology for products and
processes. Technical know-how/fees received during the year 2008-09 amounted to
about Rs. 2200 million 
Cipla's manufacturing facilities have been approved by the following regulatory
authorities:

Food and Drug Administration (FDA), USA

Medicines and Healthcare products Regulatory Agency (MHRA), UK 
Therapeutic Goods Administration (TGA), Australia 
Medicines Control Council (MCC), South Africa 
National Institute of Pharmacy (NIP), Hungary 
Pharmaceutical Inspection Convention (PIC), Germany 
World Health Organization (WHO) Department of Health, Canada 
State Institute for the Control of Drugs, Slovak Republic ANVISA, Brazil

 
Cipla products are bought by over 180 countries located in the following regions:

CURRENT STOCK VALUE

3
RS.365.35

MERGERS AND ACQUISITIO

Cipla Ltd acquires a minority stake in Cipla Medpro Mnfr (Pty) Ltd from Enaleni
Pharmaceuticals(Pty).

Cipla Ltd acquires Meditab Specialities Pvt Ltd.

Cipla Ltd acquires a minority stake in Mab Pharm. 

Cipla Ltd acquires a minority stake in Biomabs.

Cipla Ltd acquires Golden Cross and Kurkumbh.

Piramal Healthcare Ltd acquires Cipla Ltd-i-pill Brand from Cipla Ltd.

Enaleni Pharmaceuticals acquires Cipla Medpro(Pty)Ltd from Cipla Ltd

Rumor dispelled that Sandoz GmbH was seeking to acquire minority stake in Cipla Ltd.

Cipla Ltd withdraws offer to purchase remaining interest in Hon Po Group(Lobster King)Ltd.

Cipla Ltd withdraws offer for Hon Po Group(Lobster King)Ltd.

LAST SIX MONTH NEWS

30 November Cipla extends an innovative ‘Mother-Baby Pack’ for preventing mother-to-child
2010 transmission of HIV/AIDS
20 October Cipla launches the world’s first generic Pirfenidone in India, giving hope to
2010 sufferers of IPF (Idiopathic Pulmonary Fibrosis)

4
 06 July 2010 Life sciences industry in Asia grew 3.4% in 2009: survey
10 April 2010 Public Notice
23 March 2010 Piramal Healthcare Acquires "i-pill", a Leading Emergency Contraceptive
Brand from Cipla

FUTURE OUTLOOK
-Cipla reported better-than-expected earnings for the quarter endedDecember 2009 on account of
a drop in other expenses and marginallylower input costs
-At 29%, the year-on-year growth in net profit was higher than the
market estimates of 22%.
-The company’s domestic business, which contributes half of the
revenue, grew by 14%, higher than the industry growth of 12%.
-Reducing its over-dependence on the domestic business by generating
strong consistent growth in export markets is a critical factor that would
aid Cipla future growth.

COMPETITOR
1. Ranbaxy
2. Dr Reddy's Laboratories
3. Sun Pharma Industries
4. Lupin Labs
5. GlaxoSmithKline Pharma (GSK)
6. Cadila Healthcare
7. Aventis Pharma